The epidermal growth factor receptor (EGFR) family has become a widely studied pharmacological target in the therapeutic area of cancer due to its central role in the transmission of mitogenic signals, and the frequent deregulation in cancers (Fabbro et al., 2002) . PKI166, a pyrrolo-pyrimidine derivative ( Fig. 1) (Traxler et al., 1999) , is a selective inhibitor of the tyrosine kinase activity of two EGFRs (HER1/HER2). It has a potent in vitro antiproliferative activity and in vivo antitumor activity in a mouse model (Baker et al., 2002; Bruns et al., 2000; Motoyama et al., 2002; Solorzano et al., 2001 ). Its clinical development was hampered by liver toxicity findings (Traxler, 2003) . ADME studies performed in rats and dogs demonstrated that PKI166 was almost exclusively excreted in feces (~ 90% after peroral or intravenous dosing, thereof > 50% unchanged compound), with only about 3 and 5% of the dose excreted in urine of dog and rat, respectively. Bile analysis of rat indicated extensive direct Oglucuronidation. Glucuronidates apparently were then subject to colonic bacterial deconjugation before excretion or reabsorption of PKI166, the latter leading to enterohepatic recirculation (Novartis, non published data). In clinical studies, a high plasma exposure to the main metabolite ACU154 -an O-glucuronide ( Fig. 1 ) -was observed; the exposure to this metabolite was often higher than the plasma exposure to the parent compound. Against this background hepatocyte trafficking of PKI166 and its metabolites must be regarded as critical for the overall disposition of this anticancer compound. These transport processes must be considered in the evaluation of PKI166s liver toxicity.
Here we analyse the transport of PKI166 and its main metabolite ACU154 (Fig. 1) employing Madin-Darby Canine Kidney II (MDCKII) cell monolayers and liver canalicular membrane vesicles (CMVs). The employed MDCKII cells expressed one or two transporter proteins heterologously. The human multi drug resistance DMD #497R 5 associated protein 2 (MRP2) in their apical and/or the human organic anion transporting peptide 2 (OATP2) in their basal membrane (Sasaki et al., 2002) (Evers et al., 1998) as it is found in human hepatocytes. CMVs were prepared from normal Wistar and TR -rats, a mutant strain with a hereditary defect in mrp2 (Jansen et al., 1985 (Fig. 9C/D) . A similar effect was evident at 100 µM PKI166 but much less pronounced (Fig. 8C/D) .
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Discussion
In preclinical ADME studies with [ towards the apical side was about 30-fold higher than that of its glucuronide ACU154
( Fig. 2A and 3A) ; however, the expression of neither OATP2 nor MRP2 did increase this flux (Fig. 2) . ACU154 -which is formed from PKI166 in liver cells -is more hydrophilic and bulky, explaining its slower flux through MDCKII cells. Thus ACU154 depends on active transport for the efficient excretion into bile. ACU154
was shown to be a substrate of human MRP2 (Fig. 3) as well as rat mrp2 (Fig. 6 ).
This finding confirms the in vivo results obtained in rats, which indicated that mrp2 activity is critical for the hepatic elimination of PKI166. MRP2/mrp2 transports a This article has not been copyedited and formatted. The final version may differ from this version. uptake was dependent on the presence of functional mrp2 (Fig. 9) . The latter finding suggests that TCA transport by bsep is not inhibited by cytoplasmic ACU154, but depends on the presence of mrp2, that allows ACU154 to get efficiently to the bile side of hepatocytes. Mrp2 dependent inhibition of bsep activity has been described e.g. for EG in vitro (Stieger et al., 2000) and in vivo (Huang et al., 2000; Sano et al., 1993) , and for two sulphate-conjugated bile acids that were identified as mrp2
substrates (Akita et al., 2001) . Sano and colleagues found that the cholestatic effect of EG that is evident in Sprague-Dawley rats was absent in mrp2 deficient Eisai hyperbilirubinuria rats, where the biliary excretion of EG was delayed (Sano et al., 
